Journal Article (Review Article) DZNE-2022-00125

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Challenges and Opportunities of Targeting Astrocytes to Halt Neurodegenerative Disorders.

 ;  ;  ;

2021
MDPI Basel

Cells 10(8), 2019 () [10.3390/cells10082019] special issue: "The Contribution of Non-Neuronal Cells in Neurodegeneration: From Molecular Pathogenesis to Therapeutic Challenges"

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Neurodegenerative diseases are a heterogeneous group of disorders whose incidence is likely to duplicate in the next 30 years along with the progressive aging of the western population. Non-cell-specific therapeutics or therapeutics designed to tackle aberrant pathways within neurons failed to slow down or halt neurodegeneration. Yet, in the last few years, our knowledge of the importance of glial cells to maintain the central nervous system homeostasis in health conditions has increased exponentially, along with our awareness of their fundamental and multifaced role in pathological conditions. Among glial cells, astrocytes emerge as promising therapeutic targets in various neurodegenerative disorders. In this review, we present the latest evidence showing the astonishing level of specialization that astrocytes display to fulfill the demands of their neuronal partners as well as their plasticity upon injury. Then, we discuss the controversies that fuel the current debate on these cells. We tackle evidence of a potential beneficial effect of cell therapy, achieved by transplanting astrocytes or their precursors. Afterwards, we introduce the different strategies proposed to modulate astrocyte functions in neurodegeneration, ranging from lifestyle changes to environmental cues. Finally, we discuss the challenges and the recent advancements to develop astrocyte-specific delivery systems.

Keyword(s): Animals (MeSH) ; Astrocytes: drug effects (MeSH) ; Astrocytes: metabolism (MeSH) ; Central Nervous System: drug effects (MeSH) ; Central Nervous System: metabolism (MeSH) ; Central Nervous System: pathology (MeSH) ; Humans (MeSH) ; Molecular Targeted Therapy: methods (MeSH) ; Neurodegenerative Diseases: metabolism (MeSH) ; Neurodegenerative Diseases: prevention & control (MeSH) ; Neuroglia: drug effects (MeSH) ; Neuroglia: metabolism (MeSH) ; Neuronal Plasticity: drug effects (MeSH) ; Neurons: drug effects (MeSH) ; Neurons: metabolism (MeSH) ; Neuroprotective Agents: therapeutic use (MeSH) ; astrocytes ; neurodegenerative diseases ; neuroinflammation ; rehabilitation ; targeted therapy ; Neuroprotective Agents

Classification:

Note: (CC BY)

Contributing Institute(s):
  1. Molecular Neuropathology of Neurodegenerative Diseases (AG Neumann)
Research Program(s):
  1. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2021
Database coverage:
Medline ; Creative Commons Attribution CC BY (No Version) ; DOAJ ; OpenAccess ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Neumann
Full Text Collection
Public records
Publications Database

 Record created 2022-03-31, last modified 2023-09-15


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)